相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Veerisa Vimolchalao et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hironobu Hashimoto et al.
LANCET ONCOLOGY (2020)
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
Winnie Yeo et al.
BREAST (2020)
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting
M. Clemons et al.
BREAST (2020)
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study
So-Yeon Jeon et al.
CANCER RESEARCH AND TREATMENT (2019)
One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis
Yuki Okada et al.
ONCOLOGIST (2019)
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide
Piyawan Tienchaiananda et al.
ANNALS OF PALLIATIVE MEDICINE (2019)
1764PA phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE study
H Hashimoto et al.
ANNALS OF ONCOLOGY (2019)
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial
Amber B. Clemmons et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
Hitoshi Kawazoe et al.
SCIENTIFIC REPORTS (2018)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan
Alaa A. M. Osman et al.
JOURNAL OF GLOBAL ONCOLOGY (2018)
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study
Sandip Mukhopadhyay et al.
SUPPORTIVE CARE IN CANCER (2017)
Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study
L. Q. Yang et al.
EUROPEAN JOURNAL OF CANCER CARE (2017)
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy
Kazuhisa Nakashima et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
NCCN Guidelines® Insights Antiemesis, Version 2.2017 Featured Updates to the NCCN Guidelines
Michael J. Berger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Abstracts of the MASCC/ISOO 2017 Annual Meeting
SUPPORTIVE CARE IN CANCER (2017)
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
Masakazu Abe et al.
SUPPORTIVE CARE IN CANCER (2016)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin.
Hironobu Hashimoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety
Matti Aapro et al.
ONCOLOGIST (2015)
Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy
Masakazu Abe et al.
BIOMED RESEARCH INTERNATIONAL (2015)
International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice
Karin Jordan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study
Naomi Mizukami et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Ethan Basch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Lijun Tan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
Mitsue Saito et al.
LANCET ONCOLOGY (2009)
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study
Rudolph M. Navari et al.
SUPPORTIVE CARE IN CANCER (2007)
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study
RM Navari et al.
SUPPORTIVE CARE IN CANCER (2005)
分享论文
